Frontlight ResearchEarly access
Active, not recruitingPhase 3
Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)
Key facts
- Who runs it
- Kedrion S.p.A.
- Where
- Centennial, Durham, Lafayette, San Francisco, Shreveport, St. Petersburg, Toledo, and Tulsa, United StatesSee the 8 sitesAlso in 5 other countries, 13 sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 30 people, planned
- Started
- 31 Mar 2021
- Expected to end
- May 2027
- Type of study
- Interventional
- Treatments tested
- Kedrion IVIG 10%
- Record updated
- 29 May 2026
Who can take part
- Age
- 2 years to 16 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 35 criteriaShow less
Who can take part
- Written informed consent/assent obtained from the patient and his/her parent(s) or legally acceptable representative indicating that they understand the purpose of and procedures required for the study and are willing to participate in it
- Confirmed clinical diagnosis of a PID as defined by 2017 International Union of Immunological Societies (IUIS) Phenotypic Classification for Primary Immunodeficiencies (Bousfiha A, 2018 - and subsequent revisions) and The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity (Seidel MG et al., 2019 - and subsequent revisions) and requiring treatment with IVIg. Documented agammaglobulinemia (defined as the total absence of one or more classes of antibodies) or hypogammaglobulinemia (defined as low levels of one or more classes [i.e., at least 2 standard deviations under the mean level per age]); (NOTE: IVIg treatment is generally requested in the absence of IgG independently from whether other antibodies are absent)
- Male or female, age from 2 up to < 16 years, at the time of screening
- Received 200 to 800 mg/kg of a commercially available IVIg therapy in the range of 21- or 28-day intervals (±3 or ±4 days, respectively) for at least 3 infusions prior to screening; (NOTE: Other IVIgs will be prohibited after ICF signature and until study end, week 51/52)
- At least 2 documented IgG trough levels while receiving an IVIg, of ≥ 6 g/L obtained at 2 infusions within 12 months (1 must be within 6 months) prior to ICF signature
- Patient and his/her parent(s)/legal guardian(s) are willing to comply with all requirements of the protocol
- Females of child-bearing potential with a negative pregnancy test (serum or urine) and who agree to employ adequate birth control measures during the study, such as:; sexual abstinence, to be evaluated in relation to the preferred and usual lifestyle of the subject; male or female condom with or without spermicide; cap, diaphragm or sponge with spermicide; progestogen-only oral hormonal contraception, if already used in the past on medical prescription; Adequate birth control measures should be maintained throughout the study under parental control
- Authorization to access personal health information
- Patients previously participating in a clinical trial with another experimental IVIg may be enrolled if they have received stable commercially available IVIg therapy for at least 3 infusions (21 or 28 days) prior to screening
- Patients currently on treatment with any subcutaneous immunoglobulin (SCIG) can be enrolled if they are switched to stable commercially available IVIg therapy for at least 3 infusions (21 or 28 days) prior to screening
- Males or females with a body weight greater than or equal to 15 kg (≥ 15 kg)
Who cannot take part
- Newly diagnosed PID and naïve to IgG replacement therapy
- IgA deficiency with documented antibodies to IgA
- Received blood products that have not undergone viral inactivation measures within 12 months prior to ICF signature
- An acute infection as documented by culture or diagnostic imaging and/or a body temperature ≥38.5 °C (≥101.3 °F) within 7 days prior to screening
- History of a malignant disease other than properly treated carcinoma in situ of the cervix or basal cell or squamous cell carcinoma of the skin within 24 months prior to ICF signature
- Patient must not be receiving the following medication from at least 30 days prior to ICF signature:; Steroids, inhaled, oral or parenteral, at a daily dosage of ≥ 0.15 mg/kg/day of prednisone or equivalent); Other immunosuppressive drugs (including monoclonal antibodies) or chemotherapy
- Participated in another clinical study within 30 days prior to ICF signature
- Active drug or alcohol abuse or history of drug or alcohol abuse within the 6 months before screening
- Previously treated under this protocol
- History of severe or serious reactions or hypersensitivity to IVIg or other injectable forms of IgG
- History of thrombotic events including deep vein thrombosis, cerebrovascular accident, pulmonary embolism, transient ischemic attacks, or myocardial infarction, as defined by at least 1 event in patient's lifetime
- Significant protein losing enteropathy, nephrotic syndrome, or lymphangiectasia
- Acquired immunodeficiency syndrome (AIDS) and/or hepatitis B/C active disease at ICF signature
- History of pharmacoresistant epilepsy or multiple episodes of migraine (defined as at least 1 episode within 6 months of ICF signature) not controlled by medication
- Patients with any condition which, in the opinion of the Investigator, might interfere with the evaluation of the study objectives or the patient's participation in this trial
- Patients with Hypersensitivity to the active substance or to any of the excipients
- Dysgammaglobulinemia (defined as a deficiency in one or more classes of antibodies, but not severe enough to require substitutive therapy) or isolated IgG subclass deficiency, or profound primary T cell deficiency (defined as the absence or severe reduction of T lymphocytes [CD3+ < 300 cell/mm3] and an absent or particularly low proliferative response [10% of the lower normal range] to phytohaemagglutinin P [PHA])
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 times of the upper limit of normal for the laboratory designated for the study
- Moderate or severe anemia, defined according to patient's age as shown in the following table (World Health Organization, 2011) or persistent severe neutropenia (≤ 500 neutrophils per mm3) or persistent lymphopenia of less than 500 cells per microliter
- A severe chronic condition such as renal failure [defined as abnormalities in kidney structure or function that are present for more than 3 months and have health implications. The disease is classified on the basis of cause and category of glomerular filtration rate (GFR) (G1 to G5) and albuminuria (A1 to A3) (KIDIGO, 2017). See the following table], congestive heart failure (New York Heart Association III/IV), cardiomyopathy, cardiac arrhythmia associated with thromboembolic events (e.g., atrial fibrillation), unstable or advanced ischemic heart disease, hyperviscosity, or any other condition that the Investigator believes is likely to interfere with evaluation of the study drug or with satisfactory conduct of the trial
- Using an implanted venous access device
- Females who are pregnant, breast feeding or planning a pregnancy during the course of the study. Women who become pregnant during the study will be withdrawn from the study
- Direct relative of an employee of the CRO, the study site, or Kedrion
- Unable to provide informed consent
Where in United States
Also in 5 other countries, 13 sites
- IMMUNOe Health and Research CentersCentennial, United States
- Duke Children's Hospital & Health CenterDurham, United States
- Velocity Clinical Research - MedPharmics - LafayetteLafayette, United States
- Benioff Children's Hospital - Mission BaySan Francisco, United States
- Louisiana State University ShreveportShreveport, United States
- Johns Hopkins All Children's HospitalSt. Petersburg, United States
- Asthma and Allergy Center - ToledoToledo, United States
- Vital Prospects Clinical Research Institute., PCTulsa, United States
About the trial
What the trial wants to find out
The purpose of this study is to assess efficacy, safety and pharmacokinetics of Kedrion Immunoglobulin 10% (KIg10) in pediatric patients with Primary Immunodeficiency Disease (PID).
The group in the trial
- Experimental: Kedrion IVIG 10%Treatment being tested
Participants will receive intravenous infusion of Kedrion IVIG 10% at a dose of 200 to 800 milligram per kilogram (mg/kg) body weight every 21 or 28 days for period of 48 weeks.
Treatment: Kedrion IVIG 10%
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety, and Pharmacokinetics of Kedrion Intravenous Human Normal Immunoglobulin (IVIg) 10% in Pediatric Patients Affected by Primary Immunodeficiency Disease (PID)
- Record updated
- 29 May 2026